AROAF
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more
Market Cap & Net Worth: AROAF (AROAF)
AROAF (PINK:AROAF) has a market capitalization of $138.71 Million ($138.71 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #18098 globally and #6788 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AROAF's stock price $0.40 by its total outstanding shares 346787355 (346.79 Million).
AROAF Market Cap History: 2025 to 2025
AROAF's market capitalization history from 2025 to 2025. Data shows growth from $138.71 Million to $138.71 Million (0.00% CAGR).
AROAF Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AROAF's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.80x
AROAF's market cap is 1.80 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $138.71 Million | $76.97 Million | -$3.47 Million | 1.80x | N/A |
Competitor Companies of AROAF by Market Capitalization
Companies near AROAF in the global market cap rankings as of March 19, 2026.
Key companies related to AROAF by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
AROAF Historical Marketcap From 2025 to 2025
Between 2025 and today, AROAF's market cap moved from $138.71 Million to $ 138.71 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $138.71 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AROAF was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.71 Million USD |
| MoneyControl | $138.71 Million USD |
| MarketWatch | $138.71 Million USD |
| marketcap.company | $138.71 Million USD |
| Reuters | $138.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.